-
Tytuł:
-
TRAIL in oncology: From recombinant TRAIL to nano- and self-targeted TRAIL-based therapies.
-
Autorzy:
-
Dianat-Moghadam H; Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
Heidarifard M; Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Mahari A; Department of Chemical Engineering, Islamic Azad University, Ahar Branch, Ahar, Iran.
Shahgolzari M; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Keshavarz M; The Persian Gulf Tropical Medicine Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran.
Nouri M; Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Amoozgar Z; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. Electronic address: .
-
Źródło:
-
Pharmacological research [Pharmacol Res] 2020 May; Vol. 155, pp. 104716. Date of Electronic Publication: 2020 Feb 18.
-
Typ publikacji:
-
Journal Article; Research Support, Non-U.S. Gov't; Review
-
Język:
-
English
-
Imprint Name(s):
-
Publication: Oct. 2015- : Amsterdam ; Elsevier
Original Publication: London ; San Diego : Academic Press, c1989-
-
MeSH Terms:
-
Neoplasms/*metabolism
TNF-Related Apoptosis-Inducing Ligand/*metabolism
Animals ; Humans ; Molecular Targeted Therapy ; Nanomedicine ; Neoplasms/drug therapy ; Receptors, TNF-Related Apoptosis-Inducing Ligand ; Recombinant Proteins/metabolism ; Signal Transduction
-
Contributed Indexing:
-
Keywords: Bortezomib (PubChem CID: 387447); Cancer stem cell; Doxorubicin (PubChem CID: 31703); Drug delivery system; Drug resistance; Exosomes, Tumor-targeting bacteria; Mmad (PubChem CID: 10723894); ONC201(PubChem CID: 73777259); Paclitaxel (PubChem CID: 36314); Pemetrexed (PubChem CID: 135410875); Sorafenib (PubChem CID: 216239); TRAIL; Tumor-targeting viruses
-
Substance Nomenclature:
-
0 (Receptors, TNF-Related Apoptosis-Inducing Ligand)
0 (Recombinant Proteins)
0 (TNF-Related Apoptosis-Inducing Ligand)
-
Entry Date(s):
-
Date Created: 20200222 Date Completed: 20210329 Latest Revision: 20210329
-
Update Code:
-
20240105
-
DOI:
-
10.1016/j.phrs.2020.104716
-
PMID:
-
32084560
-
TNF-related apoptosis-inducing ligand (TRAIL) selectively induces the apoptosis pathway in tumor cells leading to tumor cell death. Because TRAIL induction can kill tumor cells, cancer researchers have developed many agents to target TRAIL and some of these agents have entered clinical trials in oncology. Unfortunately, these trials have failed for many reasons, including drug resistance, off-target toxicities, short half-life, and specifically in gene therapy due to the limited uptake of TRAIL genes by cancer cells. To address these drawbacks, translational researchers have utilized drug delivery platforms. Although, these platforms can improve TRAIL-based therapies, they are unable to sufficiently translate the full potential of TRAIL-targeting to clinically viable products. Herein, we first summarize the complex biology of TRAIL signaling, including TRAILs cross-talk with other signaling pathways and immune cells. Next, we focus on known resistant mechanisms to TRAIL-based therapies. Then, we discuss how nano-formulation has the potential to enhance the therapeutic efficacy of TRAIL protein. Finally, we specify strategies with the potential to overcome the challenges that cannot be addressed via nanotechnology alone, including the alternative methods of TRAIL-expressing circulating cells, tumor-targeting bacteria, viruses, and exosomes.
Competing Interests: Declaration of Competing Interest Dr. Zohreh Amoozgar is one of the patent holders (US Patent Numbers 15,311,339 and 15,503,766) for coated/protein-based particles for drug delivery. The remaining authors declare no conflict of interest.
(Copyright © 2020 Elsevier Ltd. All rights reserved.)
